# A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

> **NCT03505554** · PHASE2 · UNKNOWN · sponsor: **University of Milano Bicocca** · enrollment: 12 (estimated)

## Conditions studied

- Anaplastic Large Cell Lymphoma, ALK-Positive

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT03505554
- **Lead sponsor:** University of Milano Bicocca
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-10
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2023-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03505554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03505554, "A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03505554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*